pancreatic cancer therapy
FDA approves Revolution Medicines’ first in class targeted therapy for metastatic pancreatic cancer
67,000 new cases of pancreatic cancer are diagnosed in the US each year
Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes
The treatment can be used to delay the onset of clinical type 1 diabetes
J&J’s Icotyde approved by US FDA for plaque psoriasis
Plaque psoriasis affects over 125 million people worldwide
Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes
The insulin is designed as an alternative to daily basal insulin
Johnson & Johnson’s multiple myeloma treatment approved by US FDA
The approval was based on phase 3 data showing survival rates of 83.3% after three years
AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers
In 2022, nearly one million new patients were diagnosed with gastric cancer
iOnctura awarded €17.5m from EIC Accelerator for novel pancreatic cancer therapy
The company dosed the first patient in a phase 1b study of IOA-289 earlier this month
Novartis gets early approval for heart failure drug Entresto
It is the first worldwide indication for the in-class neprilysin inhibitor
Vertex wins FDA approval for cystic fibrosis therapy Orkambi
It is the combination therapy’s first regulatory approval
Generic Copaxone launches in US
Sandoz and Momenta Pharmaceuticals started shipping Glatopa in reaction
Novartis gets FDA nod for rare blood disorder drug
Promacta will provide a treatment option for children over 6 years old